What Is Age-Related Macular Degeneration?

The macula is a small but critically important region near the center of the retina. It provides the sharp, detailed central vision needed for everyday tasks like reading, driving, and seeing fine detail. Age-related macular degeneration is the gradual deterioration of this region, and it is a leading cause of vision loss and blindness in Americans over the age of 50. As the disease progresses, central vision becomes blurry, dark spots may appear, and fine details become increasingly difficult to distinguish.

AMD comes in two forms. The dry form, which accounts for the majority of cases, develops gradually as cellular debris called drusen accumulates beneath the retina. The wet form is less common but more aggressive — abnormal blood vessels grow beneath the macula, causing bleeding and scarring that can lead to rapid vision loss. Both forms share common underlying drivers: oxidative stress, chronic inflammation, deteriorating circulation, and declining levels of protective pigments in the retina. These biological realities formed the rationale behind the AREDS research program.

Risk factors include advancing age, smoking, a family history of the condition, high blood pressure, excessive sun exposure without UV protection, and a diet low in protective antioxidants. Understanding these risk factors is important because several of them — particularly nutritional intake — are directly modifiable. That insight is exactly what drove researchers to investigate whether targeted supplementation could make a measurable difference.

The AREDS Study: A Landmark Moment in Eye Health Research

The original Age-Related Eye Disease Study was a nationwide clinical trial sponsored by the National Eye Institute. It enrolled 4,757 participants between the ages of 55 and 80, following them over multiple years to assess whether specific nutritional supplements could affect AMD progression. The study's findings, published in 2001, were a turning point in ophthalmology. Scientists found that people at high risk of developing advanced AMD lowered their risk by about 25% when treated with a high-dose combination of vitamin C, vitamin E, beta-carotene, and zinc.

The researchers were careful to note that the benefits applied specifically to people with intermediate AMD or advanced AMD in one eye — not to those with early-stage AMD or no AMD at all. But for those in the high-risk category, the results were clinically meaningful. The same group also saw a roughly 19% reduction in the risk of vision loss caused by AMD. These numbers, modest as they may appear in isolation, represent a significant protective effect over a period of years when it comes to an irreversible condition.

What made AREDS so significant was its scale and rigor. It was one of the first large randomized controlled trials to provide solid clinical evidence that dietary supplements could alter the course of a major eye disease. The original AREDS formula was the first supplement combination shown in a major trial to meaningfully slow AMD progression. That foundation paved the way for the follow-up research that would refine and improve the formula considerably.

What the Original AREDS Formula Contained

The specific formulation used in the original AREDS trial was carefully selected based on the known biology of oxidative damage in the retina. It contained vitamin C (500 mg), vitamin E (400 IU), beta-carotene (15 mg), zinc (80 mg), and copper (2 mg). Copper was included alongside zinc because high zinc intake can deplete copper levels in the body, and maintaining that balance is important for overall health.

Each of these nutrients plays a role in protecting the eye. Vitamin C and vitamin E are potent antioxidants that help neutralize the free radicals generated by light exposure and normal metabolic activity in the retina. Zinc is a trace mineral essential to retinal function — it is found in high concentrations in the eye and plays a role in transporting vitamin A from the liver to the retina. Beta-carotene, a precursor to vitamin A, was included for its antioxidant properties and its role in supporting visual function. Together, these nutrients formed a formula that, in a well-designed clinical trial, demonstrated a statistically significant reduction in AMD progression risk.

It is worth noting that the protective effect was linked to the specific dosages used in the trial, not to everyday dietary intake. The amounts of these nutrients in the AREDS formula are significantly higher than what most people consume through food alone, which is why supplementation — rather than diet modification alone — was seen as the practical path to achieving those protective levels.

AREDS2: The Important Upgrade

The original AREDS formula was a breakthrough, but it had a significant limitation. Research emerging in the years that followed revealed that beta-carotene supplementation was associated with an increased risk of lung cancer, particularly in current and former smokers. Subsequent studies uncovered a significant risk of lung cancer linked to beta-carotene, particularly in smokers, raising serious concerns about its inclusion in the original formula. This created an obvious problem: the formula that helped protect vision was potentially harmful for a large segment of the population most at risk.

The National Eye Institute launched the Age-Related Eye Disease Study 2 (AREDS2) in 2006 specifically to address this concern. AREDS2 was a multicenter, randomized, double-masked, placebo-controlled phase 3 study enrolling 4,203 participants. Its primary goals were to evaluate whether lutein and zeaxanthin could replace beta-carotene, and whether adding omega-3 fatty acids (DHA and EPA) would further enhance the formula's effectiveness. Participants were randomized to receive lutein (10 mg) plus zeaxanthin (2 mg), DHA plus EPA, both, or a placebo alongside the base AREDS formulation.

The results, tracked over a median of five years, were clear. The AREDS2 formula, which substituted lutein and zeaxanthin for beta-carotene, not only reduced the risk of lung cancer but was also more effective at reducing the risk of AMD progression compared to the original formula. A 10-year follow-up analysis published in JAMA Ophthalmology strengthened these conclusions: participants who had been given lutein and zeaxanthin had a potential beneficial association with late AMD progression, while beta-carotene usage nearly doubled the risk of lung cancer. The case for replacing beta-carotene with lutein and zeaxanthin was compelling on both efficacy and safety grounds.

Why Lutein and Zeaxanthin Matter So Much

Lutein and zeaxanthin are carotenoids — plant-derived pigments that concentrate naturally in the macula of the human eye. They form what scientists call the macular pigment, which acts as a biological filter for harmful blue light and as an antioxidant defense system against the oxidative damage that accumulates over decades of daily exposure to light and environmental stress. These two xanthophyll carotenoids serve as blue light filters and antioxidants to protect vulnerable photoreceptor cells against light-induced oxidative stress through the absorption of short-wavelength blue light and scavenging of free radicals and reactive oxygen species.

The connection between macular pigment density and AMD risk is well established. As people age, levels of lutein and zeaxanthin in the retina tend to decline, and those with lower macular pigment density face a higher risk of AMD onset and progression. A meta-analysis of 20 randomized controlled trials found that xanthophyll carotenoid supplementation was associated with a significant increase in macular pigment optical density in both AMD patients and healthy subjects. This matters because denser macular pigment is associated with less retinal tearing and degeneration over time.

Individuals low in dietary lutein and zeaxanthin were about 25% less likely to develop advanced AMD compared to participants with similar dietary intake who did not take lutein and zeaxanthin supplements. This suggests that the benefit is particularly pronounced for people who are not getting adequate amounts of these carotenoids through diet — a common situation, since the richest dietary sources are dark leafy greens like kale and spinach, which many people don't consume in sufficient quantities. Lutein and zeaxanthin are natural pigments found in the retina that provided equal or better AMD protection than beta-carotene without its associated risks.

QN Wellness's Vision Care™ includes both lutein and beta-carotene among its key ingredients — two nutrients recognized in the AREDS research for their roles in supporting macular and visual health. The formula also incorporates blueberry extract, chrysanthemum extract, Vitamin A, and Vitamin B2, bringing together several plant-derived compounds with recognized roles in eye health support.

The Beta-Carotene Concern for Smokers

Understanding the beta-carotene issue is important for anyone choosing an eye health supplement. In food, beta-carotene is entirely safe and beneficial — it is found abundantly in carrots, sweet potatoes, and other orange and yellow vegetables. However, supplemental beta-carotene at high doses has been linked to a significantly increased lung cancer risk in people who smoke or who have smoked in the past. Current and former smokers should take the AREDS2 formula and avoid the AREDS formula with beta-carotene, which increases lung cancer risk.

There is also a biochemical reason that lutein and zeaxanthin outperform beta-carotene in this context. Beta-carotene was shown to compete with lutein and zeaxanthin — individuals who took all three nutrients had lower levels of circulating lutein and zeaxanthin compared to participants who took lutein and zeaxanthin without beta-carotene. In other words, including beta-carotene in the same formula actually reduces the absorption of the more retina-specific carotenoids. This finding alone made a compelling scientific case for the AREDS2 reformulation, independent of the lung cancer concern.

The AREDS2 formula that substituted lutein and zeaxanthin for beta-carotene has proven to be a safer choice for a broader population, including those with a history of smoking. For non-smokers, both formulas offer AMD protection, but the AREDS2 version is now generally recommended by most eye care professionals as the more effective and universally appropriate option.

Other Nutrients That Support Eye Health

While the AREDS and AREDS2 studies focused on specific formulations, a broader body of research supports the role of several other nutrients in maintaining eye health and supporting the mechanisms that protect the macula. These are worth understanding as part of the bigger picture of long-term vision wellness.

Vitamin A and Carotenoids

Vitamin A is essential for the production of rhodopsin, the light-sensitive protein in retinal cells that allows for vision in low-light conditions. It is derived in the body from beta-carotene and other provitamin A carotenoids found in plants. Adequate vitamin A intake is fundamental to basic retinal function, and deficiency can contribute to night blindness and increased retinal vulnerability. QN Wellness's Vision Care™ contains Vitamin A as part of its eye-support formulation, alongside beta-carotene, lutein, and plant-derived extracts.

Blueberry (Anthocyanins)

Blueberries are rich in anthocyanins — a class of polyphenolic antioxidants that have attracted significant research attention for their eye health effects. Preclinical studies have shown that anthocyanins may protect retinal cells, support healthy microcirculation in the eye, and reduce vascular permeability that contributes to the blood vessel leakage associated with wet AMD. Blueberry extract is one of the ingredients in QN Wellness's Vision Care™, bringing these plant-derived antioxidant compounds into a comprehensive eye support formula.

Vitamin B2 (Riboflavin)

Riboflavin, or vitamin B2, supports the function of glutathione — one of the eye's primary endogenous antioxidant defenses. Low riboflavin levels have been associated with light sensitivity and reduced visual acuity. As part of a broader nutritional strategy for eye health, ensuring adequate B2 status is a sensible step, particularly for older adults whose intake and absorption of B vitamins may decline with age. Vision Care™ includes Vitamin B2 among its ingredients, recognizing its supporting role in ocular antioxidant function.

Omega-3 Fatty Acids

DHA, an omega-3 fatty acid, is a structural component of the retina and is critical to photoreceptor function. While the AREDS2 trial did not find that adding omega-3 fatty acids to the AREDS formula produced additional measurable benefits for AMD progression, observational research consistently associates higher omega-3 dietary intake with reduced AMD risk. A meta-analysis found that people with high omega-3 dietary intake had a meaningfully lower risk of late AMD. Those looking to support general cardiovascular and eye health through omega-3 supplementation can explore QN Wellness's Omega-Tree™, which contains flaxseed oil with omega-3, omega-6, and omega-9 fatty acids.

Diet and Lifestyle: Beyond the Supplement Bottle

The AREDS research was never intended to be interpreted as a substitute for healthy living. A combination of lifestyle behaviors such as avoiding smoking, engaging in physical activity, and adopting a healthy dietary pattern like the Mediterranean diet was associated with a lower prevalence of AMD. Supplements work best as a complement to a solid nutritional foundation, not as a replacement for one.

A diet rich in dark leafy greens (spinach, kale, Swiss chard), colorful vegetables and fruits, oily fish, and nuts provides a natural concentration of lutein, zeaxanthin, omega-3 fatty acids, and antioxidant vitamins. Reducing intake of saturated fats and trans fats, limiting processed foods, and maintaining a healthy blood pressure and blood sugar level all contribute to the vascular health that the macula depends on. Quitting smoking is one of the single most impactful steps any person can take to reduce their AMD risk — the evidence on this link is consistent and substantial across many studies. Wearing UV-protective sunglasses outdoors is another practical, low-cost protective measure.

Regular eye exams are equally important. AMD can progress without obvious symptoms in its early stages, and a dilated eye exam is the only reliable way to detect it early. Early detection means earlier opportunity to act — whether that means starting an AREDS-based supplement regimen, making dietary adjustments, or working with an eye care professional on a broader management plan. Supplementation alongside healthy habits and routine care represents the most comprehensive approach available to those who want to protect their vision long-term.

Who Should Consider AREDS-Based Supplementation?

The AREDS and AREDS2 research was conducted in people who already had intermediate AMD or advanced AMD in one eye. The studies were not designed to evaluate whether the formulas prevent AMD from developing in the first place in healthy eyes — and the data do not support using AREDS-based supplements as a general prevention strategy for people without existing macular disease. For those study participants who had either no AMD or early AMD, the nutrients did not provide an apparent benefit in the original trial.

That said, people with significant risk factors — a family history of AMD, intermediate AMD confirmed by an eye doctor, heavy smoking history, or advanced AMD in one eye — are the population most likely to benefit from the evidence-based AREDS2 formula. The AREDS2 formulation is now widely recommended for patients with intermediate AMD or advanced disease in one eye, offering a modest but clinically meaningful reduction in risk of progression. Anyone in these categories should discuss supplementation with their eye care provider, who can tailor recommendations based on individual health history, smoking status, and current AMD stage.

For people without diagnosed AMD who are simply looking to support their general eye health through nutrition, a diet rich in carotenoids, antioxidant vitamins, and plant-based compounds remains the most broadly supported strategy. Targeted eye health supplements that include lutein, zeaxanthin, vitamin A, and botanical extracts can complement dietary intake, particularly when getting sufficient amounts of these nutrients from food alone proves difficult.

Supporting Your Vision with QN Wellness

At QN Wellness, we believe that wellness begins with understanding what your body needs and then providing it with plant-based nutrition that works alongside a healthy lifestyle. Our Vision Care™ formulation brings together a thoughtfully selected blend of nutrients recognized in eye health research, including lutein, beta-carotene, Vitamin A, and Vitamin B2, alongside botanical extracts like blueberry and chrysanthemum — all in a vegetarian-friendly capsule format.

Vision Care™ is designed as part of a comprehensive approach to eye wellness, supporting the nutritional needs of the macula and retina with plant-derived ingredients. It is not a treatment for AMD, and as with any supplement, we encourage you to speak with your eye care professional about whether an eye health supplement is appropriate for your specific situation — especially if you have been diagnosed with macular degeneration or are in a higher-risk group.

Alongside Vision Care™, QN Wellness offers a range of wellness supplements designed to support whole-body health. From our Omega-Tree™ flaxseed oil formula (providing omega-3, omega-6, and omega-9 fatty acids) to our Immune Care™ (featuring Vitamin C and garlic extract), our product range reflects our commitment to plant-based, vegetarian nutrition that supports your health from the inside out.